Supernus Pharmaceuticals, Inc. has officially merged with Indivior Pharmaceuticals, marking a significant change in its corporate structure. The merger, effective November 2, 2026, positions Supernus as a wholly owned subsidiary of Indivior. This transition not only alters Supernus's operational framework but also impacts its stock offerings and market presence.

As part of the merger agreement, each share of Supernus common stock will be converted into the right to receive shares of Indivior's common stock, along with cash for fractional shares. Following the merger, Supernus will cease to be a public reporting company, leading to the delisting of its common stock from the Nasdaq Global Market.

Background

Supernus Pharmaceuticals, Inc. is classified under the Standard Industrial Classification (SIC) code 2834, which pertains to Pharmaceutical Preparations. The company operates on the Nasdaq exchange under the ticker symbol SUPN. Recently, Supernus has been active in the market, filing multiple forms with the SEC, including an 8-K and a 10-Q on October 29, 2026.

What the Filing Says

The filing indicates that the merger agreement was executed on August 1, 2026, and became effective on November 2, 2026. The document states, "The Company has ceased to be a public reporting company, the Common Stock is being delisted from the Nasdaq Global Market and deregistered under the Securities Exchange Act of 1934, as amended, and the offerings of Common Stock pursuant to the Plans have been terminated." This change signifies a shift in Supernus's operational strategy.

Impact

This merger will affect Supernus's shareholders, as their shares will be converted into Indivior stock. The deregistration of Supernus's securities under the Securities Exchange Act will also impact investors and analysts who track the company's performance in the public market. Additionally, the merger could influence competition within the pharmaceutical preparations industry, as Indivior integrates Supernus's operations and resources.

What's Next

The filing does not specify what happens next for Supernus Pharmaceuticals following the merger. However, the company will likely focus on integrating its operations with Indivior and adapting to its new corporate structure.